Yükleniyor... / Loading...
This study examines the effects of a compound called Sulforaphane, compared with placebo, on the cell-protective Nrf2 signaling pathway in older adults. It enrolled men and women aged 60 and older who were below a defined fitness level. It was a non-phased study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Men and women, 60 years and older * Competent to independently give informed consent * Successful completion of screening * Maximal oxygen consumption below the 60th percentile based on gender: * Women: ≤ 21.2 mL/kg/min * Men: ≤ 30.5 mL/kg/min Exclusion Criteria: * Estrogen supplementation (in any form) within the previous 6 months * Any medication that could affect outcome measures such as statins, blood pressure medications, or anti-depressives * Use of anti-oxidant supplements, in excess of standard multi-vitamins (1 tablet/day) and/or any supplements known to target Nrf2 including resveratrol, Protandim, and sulforaphane * Current smoker * Body Mass Index (BMI) greater than 33 kg/m2 (Class I Obesity) * Any chronic illness that could affect outcome measures, including diabetes, liver or renal disease, or cancer (other than skin cancer) * History of a myocardial infarction within the last 6 months, clinically significant aortic stenosis, use of cardiac defibrillator, or uncontrolled angina * Clinically significant arrhythmia on a resting EKG or significant EKG changes during the baseline VO2 max test * Any other condition that would contraindicate maximal exercise testing, including elevated blood pressure at rest (systolic BP \>150 or diastolic BP \>90 mm Hg on at least 2 measurements, at least 10 minutes apart) or musculoskeletal problems